Skip to main content

Bioavailability

11
Pipeline Programs
12
Companies
30
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
11
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 13 programs with unclassified modality

Competitive Landscape

12 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
4 programs
4
FostamatinibPhase 1Small Molecule1 trial
NKTR-118Phase 11 trial
Naloxegol 25 mg tablet, crushed, suspended in water, given orallyPhase 11 trial
Ticagrelor OD tabletPhase 11 trial
Active Trials
NCT01208155Completed24Est. Nov 2010
NCT01520896Completed22Est. Apr 2012
NCT02446171Completed44Est. Jul 2015
+1 more trials
Pfizer
PfizerNEW YORK, NY
2 programs
2
PF-07321332/ritonavirPhase 1Small Molecule1 trial
pegvisomantPhase 11 trial
Active Trials
NCT05263921Completed12Est. May 2022
NCT01181973Completed14Est. Jan 2011
Quotient Therapeutics
Quotient TherapeuticsMA - Cambridge
1 program
1
Belumosudil TabletPhase 11 trial
Active Trials
NCT02557139Completed23Est. Oct 2015
Initiator Pharma
Initiator PharmaDenmark - Copenhagen
1 program
1
IP2015Phase 11 trial
Active Trials
NCT05728671Unknown12Est. Jul 2023
Paion
PaionGermany - Aachen
1 program
1
RemimazolamPhase 11 trial
Active Trials
NCT04113564Completed14Est. Nov 2015
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
TEPEZZAPhase 11 trial
Active Trials
NCT06563856Completed37Est. May 2021
Wockhardt
WockhardtNJ - Parsippany
1 program
1
WCK 771 IV InfusionPhase 11 trial
Active Trials
NCT05640531Completed36Est. Jun 2012
Innovation Pharmaceuticals
1 program
AX-olive oil-PP emulsionN/A1 trial
Active Trials
NCT04583722Completed13Est. Jan 2019
Handok
HandokKorea - Seoul
1 program
curminN/A1 trial
Active Trials
NCT04028739Completed24Est. Nov 2019
Takeda
TakedaTOKYO, Japan
1 program
Dexlansoprazole Delayed Release Orally Disintegrating TabletsPHASE_11 trial
Active Trials
NCT02064907Completed52Est. Apr 2014
Galapagos
Galapagos2800 MECHELEN, Belgium
1 program
FilgotinibPHASE_1Small Molecule1 trial
Active Trials
NCT06043739Completed12Est. Nov 2023
Sanofi
SanofiPARIS, France
1 program
RisedronatePHASE_15 trials
Active Trials
NCT00717145Completed94Est. Sep 2008
NCT00755872Completed76Est. Feb 2008
NCT00460733Completed141Est. Sep 2011
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SanofiRisedronate
SanofiRisedronate
SanofiRisedronate
SanofiRisedronate
SanofiRisedronate
SanofiRisedronate
SanofiRisedronate
SanofiRisedronate
SanofiRisedronate
SanofiRisedronate
SanofiRisedronate
SanofiRisedronate
GalapagosFilgotinib
Initiator PharmaIP2015
PfizerPF-07321332/ritonavir

Showing 15 of 30 trials with date data

Clinical Trials (30)

Total enrollment: 7,226 patients across 30 trials

SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture.

Start: Mar 2007Est. completion: Sep 2011141 patients
Phase 4Completed

ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week

Start: May 20057 patients
Phase 4Terminated

OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women

Start: Mar 2004Est. completion: Mar 2007290 patients
Phase 4Completed

Risedronate Sodium in Post Menopausal Osteoporosis

Start: Jan 2004246 patients
Phase 4Completed

Satisfaction and Compliance of Risedronate in PMO

Start: Oct 2003202 patients
Phase 4Completed

POWER Point of Care Effect on Satisfaction of Treatment

Start: Feb 2003Est. completion: Nov 20042,433 patients
Phase 4Completed

Risedronate in the Prevention of Osteoporosis in Postmenopausal Women

Start: Sep 2002Est. completion: Jun 2004260 patients
Phase 4Completed

Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer

Start: Jan 2007Est. completion: Feb 2009160 patients
Phase 3Completed

A Study of Monthly Risedronate for Osteoporosis

Start: Oct 2005Est. completion: Apr 20081,294 patients
Phase 3Completed

Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women

Start: Jul 2004Est. completion: Mar 20071,231 patients
Phase 3Completed

Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women

Start: Dec 2002Est. completion: Apr 2005171 patients
Phase 3Completed

Risedronate in Postmenopausal Women With Low Bone Density

Start: Nov 2002Est. completion: Jun 2003150 patients
Phase 2Completed

Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects

Start: Sep 2023Est. completion: Nov 202312 patients
Phase 1Completed

Bioavailability Study to Compare Liquid vs Two Solid Formulations of IP2015

Start: Feb 2023Est. completion: Jul 202312 patients
Phase 1Unknown
NCT05263921PfizerPF-07321332/ritonavir

Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants

Start: Mar 2022Est. completion: May 202212 patients
Phase 1Completed

A Study of TEPEZZA Subcutaneous Administration in Healthy Adults

Start: Sep 2020Est. completion: May 202137 patients
Phase 1Completed
NCT04113564PaionRemimazolam

Absolute Oral Bioavailability of Remimazolam

Start: Nov 2015Est. completion: Nov 201514 patients
Phase 1Completed

Bioavailability of Belumosudil (KD025) in Healthy Male Subjects

Start: Sep 2015Est. completion: Oct 201523 patients
Phase 1Completed
NCT02400333AstraZenecaTicagrelor OD tablet

Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet

Start: Jun 2015Est. completion: Jul 2015100 patients
Phase 1Completed
NCT02446171AstraZenecaNaloxegol 25 mg tablet, crushed, suspended in water, given orally

A Bioavailability Study With Alternate Methods of Administration of Naloxegol Tablets, and Solution

Start: May 2015Est. completion: Jul 201544 patients
Phase 1Completed
NCT02064907TakedaDexlansoprazole Delayed Release Orally Disintegrating Tablets

Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants

Start: Feb 2014Est. completion: Apr 201452 patients
Phase 1Completed

Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118

Start: Feb 2012Est. completion: Apr 201222 patients
Phase 1Completed
NCT05640531WockhardtWCK 771 IV Infusion

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771

Start: Dec 2011Est. completion: Jun 201236 patients
Phase 1Completed

Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects

Start: Oct 2010Est. completion: Jan 201114 patients
Phase 1Completed

Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets

Start: Sep 2010Est. completion: Nov 201024 patients
Phase 1Completed

Food Effects on the Relative Bioavailability of Different Dosages of Risedronate

Start: Jul 2008Est. completion: Sep 200894 patients
Phase 1Completed

Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate

Start: Nov 2007Est. completion: Feb 200876 patients
Phase 1Completed

Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose

Start: Nov 2002Est. completion: Feb 200432 patients
Phase 1Completed

Theracurmin vs Curcumin Bioavailability Study

Start: Jul 2019Est. completion: Nov 201924 patients
N/ACompleted

Evaluating Astaxanthin Bioavailability, and a New Technology for Improving it, Using Natural Food Materials Only

Start: Jul 2018Est. completion: Jan 201913 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.